BriaCell Therapeutics Corp. (BCTX)
After hours:
- GlobeNewswire
BriaCell Adds Additional Clinical Sites to Broaden Patient Access and Further Boost Enrollment
PHILADELPHIA and VANCOUVER, British Columbia, May 18, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announces that it has activated Hoag Memorial Hospital Presbyterian (“Hoag”) and re-engaged Sylvester Comprehensive Cancer Center, part of UHealth – the University of Miami Health System, as two additional clinical sites
- Simply Wall St.
We're Hopeful That BriaCell Therapeutics (TSE:BCT) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. Indeed, BriaCell Therapeutics...
- GlobeNewswire
BriaCell Receives FDA Fast Track Approval for Targeted Breast Cancer Immunotherapy
U.S. Food and Drug Administration (FDA) has granted Fast Track status to BriaCell’s lead candidate, Bria-IMT™, for the treatment of metastatic breast cancer.Fast Track improves the speed and frequency of communication with FDA, potentially leading to earlier drug approval and access by patients.BriaCell is currently enrolling and dosing advanced breast cancer patients in a Phase I/IIa study, now with Fast Track designation. PHILADELPHIA and VANCOUVER, British Columbia, April 13, 2022 (GLOBE NEWS
